Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erding – page 82

1 344 clinical trials in Erding, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erding at a glance
1 344
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 344 trials in Erding

Open in trial search

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Universitaetsklinikum Erlangen AöR

Study of Cemiplimab Alone and with RP1 for Patients with Advanced Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Replimune Inc.

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not recruiting

Study Comparing Abatacept and Adalimumab for Adults with Early Rheumatoid Arthritis Not Responding to Methotrexate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Pemphigoid

Not recruiting

Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erding

What the registry says about research in the country

01 Hematologic Disorders

Innovative research focusing on Myelodysplastic Syndrome (MDS), comparing novel therapeutic approaches for patients with lower-risk conditions. The studies aim to evaluate treatment effectiveness in managing blood cell production disorders.

  • Lower-risk MDS management
  • Blood cell production therapy
  • Treatment conversion studies

Current trials are investigating comparative effectiveness of different therapeutic agents in managing transfusion dependency.

02 Blood Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict treatment outcomes. Studies focus on understanding hydroxyurea resistance patterns in affected patients.

  • Treatment resistance evaluation
  • AI-driven predictions
  • Therapeutic monitoring

Research combines traditional clinical approaches with modern machine learning techniques to optimize treatment strategies.

03 Cardiovascular Medicine

Groundbreaking research on acute coronary syndrome and atrial fibrillation, exploring optimized antiplatelet therapy protocols. Studies evaluate new approaches for patients undergoing percutaneous coronary intervention.

  • Antiplatelet therapy optimization
  • Cardiac intervention outcomes
  • Bleeding risk management

Investigations focus on balancing therapeutic efficacy with safety in complex cardiac conditions.

04 Advanced Myelofibrosis

Clinical investigations of intermediate and high-risk myelofibrosis, exploring combination therapies and novel treatment approaches. Research aims to establish optimal dosing strategies for enhanced patient outcomes.

  • Combination therapy assessment
  • Treatment tolerability studies
  • Dose optimization research

Studies focus on developing safer and more effective treatment protocols for advanced stages of the disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.